Informativa su Privacy e Cookies
Questo sito utilizza cookie tecnici funzionali, cookie analitici di terze parti anonimizzati, e cookie di terze parti che potrebbero profilare: accedendo a qualunque elemento/area del sito al di fuori di questo banner, acconsenti a ricevere i cookie secondo le tue Preferenze. Puoi liberamente consentire, negare o impostare le tue preferenze sull\'utilizzo dei Cookies tramite i link di seguito. Se vuoi saperne di più puoi consultare la pagina Informazioni su Privacy e Cookies. Ti ricordo che i Cookies saranno registrati sul tuo browser solo a seguito del tuo consenso e secondo la modalità tecniche consentite dai produttori software, puoi liberamente cancellare i Cookies in qualsiasi momento tramite l\'apposita funzione del tuo browser.  Se non consenti l\'utilizzo di alcuni Cookies si potrebbero verificare malfunzionamenti delle pagine web oppure alcuni contenuti potrebbero non funzionare. [user_consent_state] [cookie_audit columns=\"cookie,description\" heading=\"The below list details the cookies used in our website.\"]
Always Active
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.

No cookies to display.

Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.

No cookies to display.

Operational challenges and considerations for COVID-19 research in humanitarian settings: A qualitative study of a project in Eastern Democratic Republic of the Congo and South Sudan

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

Since the beginning of the COVID-19 pandemic, much research has been conducted globally, but relatively few studies have been carried out in complex emergency settings that pose numerous operational challenges. We conducted a qualitative study to explore the barriers and enablers of a COVID-19 cohort study conducted in South Sudan and Eastern Democratic Republic of the Congo, to inform future research on COVID-19 and infectious diseases in humanitarian settings. We used a case study design...

SARS-CoV-2 Infections and Reinfections among Fully Vaccinated and Unvaccinated University Athletes – 15 States, January – November 2021

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

CONCLUSIONS: This paper adds to the knowledge of COVID-19 infections among fully vaccinated individuals in college-aged populations. The level of infections among fully vaccinated student athletes indicates the need for maintaining precautions to prevent infection. Further study of COVID-19 vaccination, infection, and reinfection among the well-resourced and diverse population of student athletes might contribute further understanding of factors that play a role in health equity among young...

Vasoactive intestinal peptide: a potential target for antiviral therapy

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

Viral infection is clinically common and some viral diseases, such as the ongoing global outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), have high morbidity and mortality. However, most viral infections are currently lacking in specific therapeutic agents and effective prophylactic vaccines, due to inadequate response, increased rate of drug resistance and severe adverse side effects. Therefore, it is urgent to find new...

Spatially Patterned Neutralizing Icosahedral DNA Nanocage for Efficient SARS-CoV-2 Blocking

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

Broad-spectrum anti-SARS-CoV-2 strategies that can inhibit the infection of wild-type and mutant strains would alleviate their threats to global public health. Here, we propose an icosahedral DNA framework for the assembly of up to 30 spatially arranged neutralizing aptamers (IDNA-30) to inhibit viral infection. Each triangular plane of IDNA-30 is composed of three precisely positioned aptamers topologically matching the SARS-CoV-2 spike trimer, thus forming a multivalent spatially patterned...

Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID-19 pandemic disease, which is caused by SARS-CoV-2. The method is based on the first derivative synchronous spectrofluorimetry approach for the measurement of remdesivir and favipiravir. This was accomplished at 251 nm and 335 nm respectively using the first derivative order at delta lambda of 140 nm. A...

Antibody response to BNT162b2 mRNA vaccine in gingival crevicular fluid

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

CONCLUSION: This study establishes GCF and saliva as viable alternative non-invasive sources to monitor levels of antibodies following vaccination, with GCF demonstrating feasibility as a biofluid source for the detection of antibodies against SARS-CoV-2 S1-RBD antigen. This article is protected by copyright. All rights reserved.

Interleukin-6 blocking therapy for COVID-19: From immune pathogenesis to clinical outcomes

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

As a newly emerged infectious disease, the coronavirus disease 2019 (COVID-19) has caused millions of deaths, resulting in a global health challenge. Currently, several vaccines have been approved with significant benefits against disease transmission. However, effective therapies are still needed for the clinical management of infected COVID-19 patients. Available evidence has indicated elevated levels of proinflammatory cytokines, including interleukin-6 (IL-6), in COVID-19 patients, with...

IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

Monoclonal antibodies are an efficacious therapy against SARS-CoV-2. However, rapid viral mutagenesis, led to escape from most of these therapies, outlining the need for an antibody cocktail with a broad neutralizing potency. Using an unbiased interrogation of the memory B cell repertoire of convalescent COVID-19 patients, we identified human antibodies with broad antiviral activity in vitro and efficacy in vivo against all tested SARS-CoV-2 variants of concern, including Delta, Omicron BA.1 and...

Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

In this review, we discuss the epidemiological dynamics of different viral infections to project how the transition from a pandemic to endemic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) might take shape. Drawing from theories of disease invasion and transmission dynamics, waning immunity in the face of viral evolution and antigenic drift, and empirical data from influenza, dengue, and seasonal coronaviruses, we discuss the putative periodicity, severity, and age dynamics of...

Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years – United States, June 2022

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) amendments for the mRNA-1273 (Moderna) COVID-19 vaccine for use in children aged 6 months-5 years, administered as 2 doses (25 µg [0.25 mL] each), 4 weeks apart, and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine for use in children aged 6 months-4 years, administered as 3 doses (3 µg [0.2 mL] each), at intervals of 3 weeks between doses 1 and 2 and ≥8 weeks between doses 2 and 3. On June 18, 2022, the...

Ab-CoV: a curated database for binding affinity and neutralization profiles of coronavirus related antibodies

Di |2022-06-30T01:00:00+02:00Giugno 30th, 2022|Categorie: Coronavirus PubMed|

SUMMARY: We have developed a database, Ab-CoV, which contains manually curated experimental interaction profiles of 1780 coronavirus related neutralizing antibodies. It contains more than 3200 datapoints on half maximal inhibitory concentration (IC50), half maximal effective concentration (EC50) and binding affinity (KD). Each data with experimentally known three-dimensional structures are complemented with predicted change in stability and affinity of all possible point mutations of interface...

Torna in cima